Skip to Content

Real-World Treatment Patterns of Nivolumab + Cabozantinib Compared with Other 1L IO Combinations in mRCC

Interview: Cherrishe Brown-Bickerstaff, PhD, MPH, Senior Observational Researcher at Ontada, discusses the clinical impact of nivolumab + cabozantinib in metastatic renal cell carcinoma.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top